Ling-Dong Xu

Ling-Dong Xu

Auto-generated profile, based on publicly available information

Ling-Dong Xu

Laboratory Animal Center, Zhejiang University, Hangzhou, 310058, China; Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
FZFei Zhang
Fei Zhang
LXLing-Dong Xu
Ling-Dong Xu
QZQian Zhang
Qian Zhang
AWAilian Wang
Ailian Wang
XYXinyuan Yu
Xinyuan Yu
YHYao-Wei Huang
Yao-Wei Huang

24 August 2023 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
LZLina Zhou
Lina Zhou
SWShuai Wang
Shuai Wang
WHWei Hu
Wei Hu
XLXiaoqian Liu
Xiaoqian Liu
LXLingdong Xu
Lingdong Xu
LWLie Wang
Lie Wang
T cells require rapid proliferation to initiate adaptive immunity to prevent pathogen attacks. The nucleolus, a distinct subnuclear membrane-less compartment for ribosomal biogenesis, is indispensable for cell proliferation. However, specific nucleolar proteins involved in rapid T cell proliferation and their underlying molecular regulatory mechanism remain elusive. Here, we identified an essential nucleolar protein, DCAF13, in T cells and revealed its significant regulation of rapid T cell proliferation. Its depletion drastically impairs T cell proliferation due to severe 18S rRNA maturation failure, consequent abnormal ribosome assembly in nucleoli, and insufficient production of nascent proteins. Mechanistically, we propose that DCAF13 promotes NPM1 phase separation to accelerate pre-RNA enrichment and its endonuclease UTP23 for 18S rRNA maturation during T cell proliferation. Our findings reveal the modulatory effect of nucleolar NPM1/DCAF13 phase separation on ribosomal maturation to ensure rapid T cell proliferation and further pathogen clearance for the first time.

1 August 2021 in Microbial Pathogenesis
Verified
Journal Article
Closed access
PZPengwei Zhao
Pengwei Zhao
LXLing-Dong Xu
Ling-Dong Xu
YZYating Zhang
Yating Zhang
HCHongwei Cao
Hongwei Cao
RCRuiai Chen
Ruiai Chen
YHYao-Wei Huang
Yao-Wei Huang

28 June 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
CCChu Chen
Chu Chen
YLYa-Li Li
Ya-Li Li
FLFang-Li Lv
Fang-Li Lv
LXLing-Dong Xu
Ling-Dong Xu
YHYao-Wei Huang
Yao-Wei Huang
Although feline coronavirus (FCoV) infection is extremely common in cats, there are currently few effective treatments. A peptide derived from the heptad repeat 2 (HR2) domain of the coronavirus (CoV) spike protein has shown effective for inhibition of various human and animal CoVs in vitro, but further use of FCoV-HR2 in vivo has been limited by lack of practical delivery vectors and small animal infection model. To overcome these technical challenges, we first constructed a recombinant Bacillus subtilis (rBSCotB-HR2P) expressing spore coat protein B (CotB) fused to an HR2-derived peptide (HR2P) from a serotype II feline enteric CoV (FECV). Immunogenic capacity was evaluated in mice after intragastric or intranasal administration, showing that recombinant spores could trigger strong specific cellular and humoral immune responses. Furthermore, we developed a novel mouse model for FECV infection by transduction with its primary receptor (feline aminopeptidase N) using an E1/E3-deleted adenovirus type 5 vector. This model can be used to study the antiviral immune response and evaluate vaccines or drugs, and is an applicable choice to replace cats for the study of FECV. Oral administration of rBSCotB-HR2P in this mouse model effectively protected against FECV challenge and significantly reduced pathology in the digestive tract. Owing to its safety, low cost, and probiotic features, rBSCotB-HR2P is a promising oral vaccine candidate for use against FECV/FCoV infection in cats.

16 April 2024 in Microbes and Infection
Verified
Journal Article
Closed access
LXLing-Dong Xu
Ling-Dong Xu
FZFei Zhang
Fei Zhang
Pinglong XuPinglong Xu
Pinglong Xu
YHYao-Wei Huang
Yao-Wei Huang

1 February 2024 in Journal of Zhejiang University (Medical Sciences)
Verified
Journal Article
Open access
PDF file
LXLingdong Xu
Lingdong Xu
YXYifan Xu
Yifan Xu
FZFei Zhang
Fei Zhang
Pinglong XuPinglong Xu
Pinglong Xu
LWLie Wang
Lie Wang
Hepatocellular carcinoma (HCC) is a serious neoplastic disease with increasing incidence and mortality, accounting for 90% of all liver cancers. Hepatitis viruses are the major causative agents in the development of HCC. Hepatitis A virus (HAV) primarily causes acute infections, which is associated with HCC to a certain extent, as shown by clinicopathological studies. Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections lead to persistent liver inflammation and cirrhosis, disrupt multiple pathways associated with cellular apoptosis and proliferation, and are the most common viral precursors of HCC. In particular, mutations in the HBV HBx gene are closely associated with the incidence of HCC, while the expression of HCV core proteins contributes to hepatocellular lipid accumulation, thereby promoting tumourigenesis. In the clinical setting, hepatitis D virus (HDV) frequently co-infects with HBV, increasing the risk of chronic hepatitis. Hepatitis E virus (HEV) usually causes acute infections, however, chronic infections of HEV are increasing recently, particularly in immuno-compromised patients and organ transplant recipients, which may increase the risk of progression to cirrhosis and the occurrence of HCC. Early detection, effective intervention and vaccination against these viruses may significantly reduce the incidence of liver cancer, while mechanistic insights into the interplay between hepatitis viruses and HCC may facilitate the development of more effective intervention strategies. This article provides a comprehensive overview of hepatitis viruses and reviews recent advances in research on aberrant hepatic immune responses and the pathogenesis of HCC due to viral infection.